Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
A prodrug rapidly hydrolysed after injection to valdecoxib, which selectively inhibits COX-2-mediated prostaglandin synthesis and reduces pain and inflammation.
Indications / reported uses
Short-term treatment of postoperative pain in adults with injectable formulations, according to the product label.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Parecoxib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Parecoxib Permitted Daily Exposure (PDE) report (the Parecoxib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Parecoxib Occupational Exposure Limit (OEL) report (the Parecoxib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.